A study to see if enzalutamide could help patients with prostate cancer have more time before their cancer starts to spread to other parts of the body or dying from any cause

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Category & Conditions:
Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
Open Plain Language Summary Result:Click here